ArticleAllergy2025
Meteorin-like protein/METRNL/Interleukin-41 ameliorates atopic dermatitis-like inflammation.
Article in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Metrnl in diabetes and its complications: divergent evidence and translational prospects.Journal of translational medicine · 2026Review
- Metrnl in health and disease: tissue-specific actions and signaling networks.Apoptosis : an international journal on programmed cell death · 2026Review
- Metrnl and macrophage polarization: role in skeletal muscle homeostasis and therapeutic potential.Frontiers in immunology · 2026Review
- Article
- METRNL mitigates oxidative stress and inflammatory drawbacks in ovalbumin/lipopolysaccharide-induced allergic airway diseases via the IKK/IκB/NF-κB signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Meteorin-β: A Novel Biomarker and Therapeutic Target on Its Way to the Regulation of Human Diseases.International journal of molecular sciences · 2025Review
- Claudin18.2-positive gastric cancer-specific changes in neoadjuvant chemotherapy-driven immunosuppressive tumor microenvironment.British journal of cancer · 2025Article
- Meteorin-like protein/METRNL/Interleukin-41 ameliorates atopic dermatitis-like inflammation.Allergy · 2025Article
- Metrnl and Cardiomyopathies: From Molecular Mechanisms to Therapeutic Insights.Journal of cellular and molecular medicine · 2025Review
- Metrnl/Meteorin-like/IL-41, a novel regulator of bone metabolism and disease activity in ankylosing spondylitis: based on multi-omics analysis.Frontiers in immunology · 2025Article
- Low Circulating Metrnl Levels are Linked to Higher Abdominal Fat in Elderly T2DM Patients: A Gender-Based Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- A multidimensional analysis of prognostic factors in atopic dermatitis.Frontiers in medicine · 2025Review
- Metrnl: a promising biomarker and therapeutic target for cardiovascular and metabolic diseases.Cell communication and signaling : CCS · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundMeteorin-like protein (METRNL)/Interleukin-41 (IL-41) is a novel immune-secreted cytokine/myokine involved in several inflammatory diseases. However, how METRNL exerts its regulatory properties on skin inflammation remains elusive. This study aims to elucidate the functionality and regulatory mechanism of METRNL in atopic dermatitis (AD).
methodsMETRNL levels were determined in skin and serum samples from patients with AD and subsequently verified in the vitamin D3 analogue MC903-induced AD-like mice model. The cellular target of METRNL activity was identified by multiplex immunostaining, single-cell RNA-seq and RNA-seq.
resultsMETRNL was significantly upregulated in lesions and serum of patients with dermatitis compared to healthy controls (p <.05). Following repeated MC903 exposure, AD model mice displayed elevated levels of METRNL in both ears and serum. Administration of recombinant murine METRNL protein (rmMETRNL) ameliorated allergic skin inflammation and hallmarks of AD in mice, whereas blocking of METRNL signaling led to the opposite. METRNL enhanced β-Catenin activation, limited the expression of Th2-related molecules that attract the accumulation of Arginase-1 (Arg1)
conclusionsMETRNL can bind to KIT receptor and subsequently alleviate the allergic inflammation of AD by inhibiting the expansion of immune cells, and downregulating inflammatory gene expression by regulating the level of active WNT pathway molecule β-Catenin.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.